DBVT · Dbv Technologies S.A. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $5.64M | $4.15M | $15.73M | $4.84M | $5.71M | $11.28M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $116.68M | $89.34M | $60.22M | $75.54M | $70.34M | $101.61M |
| SG&A | $32.79M | $28.74M | $29.50M | $24.32M | $30.52M | $35.08M |
| Total Operating Expenses | $152.69M | $120.74M | $92.16M | $101.47M | $104.32M | $170.12M |
| D&A | $2.99M | $2.72M | $3.60M | $2.70M | $4.40M | $4.40M |
| Operating Income | ($147.06M) | ($116.59M) | ($76.43M) | ($96.63M) | ($98.61M) | ($158.84M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $491.0K | $55.0K | $7.0K | $70.0K | ($381.0K) | ($10.0K) |
| Net Income | ($146.95M) | ($113.92M) | ($72.73M) | ($96.27M) | ($97.81M) | ($159.56M) |
| EPS - Basic | ($1.05) | ($1.17) | ($1.52) | ($3.56) | - | - |
| EPS - Diluted | ($1.05) | ($1.17) | ($1.52) | ($3.56) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $194.17M | $32.46M | $141.37M | $209.19M | $77.30M | $140.57M |
| Accounts Receivable | - | - | $0 | $0 | $0 | $2.23M |
| Inventory | - | - | - | - | - | $2.29M |
| Accounts Payable | $40.94M | $22.03M | $23.30M | $14.47M | $11.43M | $24.00M |
| Current Assets | $212.94M | $44.39M | $158.91M | $223.07M | $114.39M | $204.55M |
| Total Assets | $233.72M | $65.66M | $182.99M | $246.52M | $146.72M | $271.73M |
| Current Liabilities | $58.02M | $31.14M | $37.34M | $29.52M | $31.40M | $54.00M |
| Long-term Debt | - | - | - | $510.0K | $1.27M | $648.0K |
| Total Liabilities | $64.95M | $38.27M | $42.80M | $52.06M | $47.45M | $78.54M |
| Stockholders' Equity | $168.77M | $27.39M | $140.19M | $194.45M | $99.27M | $138.87M |
| Retained Earnings | ($393.13M) | ($286.38M) | ($238.86M) | ($259.58M) | ($258.53M) | ($798.99M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($121.18M) | ($104.47M) | ($79.65M) | ($55.67M) | ($108.24M) | ($165.61M) |
| Investing Cash Flow | ($1.37M) | ($757.0K) | ($808.0K) | ($100.0K) | ($433.0K) | ($2.87M) |
| Financing Cash Flow | $276.18M | $587.0K | $6.77M | $194.12M | $274.0K | $149.55M |
| CapEx | $532.0K | $2.34M | $677.0K | $754.0K | $910.0K | $2.73M |
| Free Cash Flow | ($121.71M) | ($106.81M) | ($80.33M) | ($56.42M) | ($109.15M) | ($168.34M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -2609.2% | -2808.7% | -486.0% | -1994.9% | -1727.6% | -1408.7% |
| EBITDA margin | -2556.2% | -2743.1% | -463.1% | -1939.1% | -1650.6% | -1369.7% |
| Net margin | -2607.3% | -2744.4% | -462.4% | -1987.5% | -1713.5% | -1415.0% |
| Free cash flow margin | -2159.6% | -2573.2% | -510.7% | -1164.7% | -1912.3% | -1492.9% |
| FCF / Net income | 0.83 | 0.94 | 1.10 | 0.59 | 1.12 | 1.06 |
| R&D / Revenue | 2070.3% | 2152.3% | 382.9% | 1559.5% | 1232.2% | 901.1% |
| SG&A / Revenue | 581.8% | 692.3% | 187.6% | 502.1% | 534.7% | 311.1% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -62.9% | -173.5% | -39.7% | -39.1% | -66.7% | -58.7% |
| Return on equity | -87.1% | -416.0% | -51.9% | -49.5% | -98.5% | -114.9% |
| Return on invested capital | - | - | - | -39.2% | -77.5% | -89.9% |
| Liquidity | ||||||
| Current ratio | 3.67 | 1.43 | 4.26 | 7.56 | 3.64 | 3.79 |
| Quick ratio | 3.67 | 1.43 | 4.26 | 7.56 | 3.64 | 3.75 |
| Cash ratio | 3.35 | 1.04 | 3.79 | 7.09 | 2.46 | 2.60 |
| Leverage | ||||||
| Debt / Equity | - | - | - | 0.00 | 0.01 | 0.00 |
| Debt / Assets | - | - | - | 0.00 | 0.01 | 0.00 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.38 | 2.40 | 1.31 | 1.27 | 1.48 | 1.96 |
| Liabilities / Assets | 0.28 | 0.58 | 0.23 | 0.21 | 0.32 | 0.29 |
| Efficiency | ||||||
| Asset turnover | 0.02 | 0.06 | 0.09 | 0.02 | 0.04 | 0.04 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | 0d | 0d | 0d | 72d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 15.9x | 10.9x | 1.3x | 0.9x | - | - |
| P / S | 474.7x | 72.2x | 11.5x | 34.7x | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 35.8% | -73.6% | 224.7% | -15.1% | -49.4% | - |
| Revenue CAGR (3y) | 5.2% | -10.1% | 11.7% | - | - | - |
| Revenue CAGR (5y) | -13.0% | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -26.1% | -52.5% | 20.9% | 2.0% | 37.9% | - |
| Net income growth (YoY) | -29.0% | -56.6% | 24.5% | 1.6% | 38.7% | - |
| EPS growth (YoY) | 10.3% | 23.0% | 57.3% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -14.0% | -33.0% | -42.4% | 48.3% | 35.2% | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 516.2% | -80.5% | -27.9% | 95.9% | -28.5% | - |
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-1.79
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing DBV Technologies S.A. against the 5 most active filers in the same SIC group.